Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Clinical Immunology
Published in: Journal of Clinical Immunology 1/2011

01-02-2011

Substance P Enhances Th17 Phenotype in Individuals with Generalized Anxiety Disorder: an Event Resistant to Glucocorticoid Inhibition

Authors: Priscila O. Barros, Thais B. Ferreira, Morgana M. M. Vieira, Carla Renata M. Almeida, Carlos Fernando Araújo-Lima, Renato G. Silva-Filho, Joana Hygino, Regis M. Andrade, Arnaldo F. Andrade, Cleonice A. Bento

Published in: Journal of Clinical Immunology | Issue 1/2011

Login to get access

Abstract

Our objective was to evaluate the effect of stress-related dose of substance P (SP) on the in vitro proliferation and cytokine production in polyclonally activated T cells from healthy individuals or individuals with generalized anxiety disorder (GAD). Our results demonstrated that cell cultures from GAD group proliferated less following T cell activation, as compared with control group. The addition of SP enhanced, while the glucocorticoid (GC) reduced, the proliferative response in activated cell cultures from healthy but not from GAD individuals. The cytokine profile in GAD individuals revealed Th1 and Th2 deficiencies were associated with dominate Th17 phenotype which was enhanced by SP. Differently from control, the production of Th17 cytokines in GAD individuals was not affected by GC. In conclusion, our results show that complex T cell functional dysregulation in GAD individuals is significantly amplified by SP. These immune abnormalities can have impact in increasing the susceptibility to infectious diseases and inflammatory/autoimmune disorders in anxious individuals.
Literature
1.
Lazarczyk M, Matyja E, Lipkowski A. Substance P and its receptors—a potencial target for novel medicines in malignant brain tumour therapies (mini-review). Folia Neuropathol. 2007;45(3):99–107.PubMed
2.
O’Connor TM, O’Connell J, O’Brien D, Goode T, Bredin CP, Shanahan F. The role os substante P in inflammatory disease. J Cell Physiol. 2004;201:167–80.CrossRefPubMed
3.
Hokfelt T, Pernow B, Wahren J. Substance P: a Pioneer amongst neuropeptides. J Intern Med. 2001;249:27–40.CrossRefPubMed
4.
Zhang Y, Berger A, Milne CD, Paige CJ. Tachykinins in the immune system. Curr Drug Targets. 2006;7:1011–20.CrossRefPubMed
5.
Lai JP, Douglas SD, Ho WZ. Human lymphocytes express substance P and its receptor. J Neuroimmunol. 1998;86:80–6.CrossRefPubMed
6.
Marriott I, Bost KL. IL-4 and IFN-gamma up-regulate substance P receptor expression in murine peritoneal macrophages. J Immunol. 2000;165:182–91.PubMed
7.
Lighvani S, Huang X, Trivedi PP, Swanborg RH, Hazlett LD. Substance P regulates natural killer cell interferon-y production and resistance to Pseudomonas aeruginosa infection. Eur J Immunol. 2005;35:1567–75.CrossRefPubMed
8.
Laurenzi MA, Persson MA, Dalsgaard CJ, Haegerstrand A. The neuropeptide substance P stimulates production of interleukin 1 in human blood monocytes: activated cells are preferentially influenced by the neuropeptide. Scand J Immunol. 1990;31:529–33.CrossRefPubMed
9.
Gutcher I, Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest. 2007;117:1119–25.CrossRefPubMed
10.
Crozat K, Vivier E, Dalod M. Crosstalk between components of the innate immune system: promoting anti-microbial defenses and avoiding immunopathologies. Immunol Rev. 2009;227:129–49.CrossRefPubMed
11.
Ekkens MJ, Liu Z, Liu Q, Whitmire J, Xiao S, et al. The role of OX40 ligand interactions in the development of the Th2 response to the gastrointestinal nematode parasite Heligmosomoides polygyrus. J Immunol. 2003;170(1):384–93.PubMed
12.
Wilson NJ, Boniface K, Chan JR, McKenzie B, Blumenschein WM, et al. de Waal Malefyt R: Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950–7.CrossRefPubMed
13.
Andoh A, Takaya H, Makino J, Sato H, Bamba S, et al. Cooperation of interleukin-17 and interferon-gamma on chemokine secretion in human fetal intestinal epithelial cells. Clin Exp Immunol. 2001;125:56–63.CrossRefPubMed
14.
Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, et al. IL-17 stimulates the production and expression of pro-inflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol. 1998;160:3513–21.PubMed
15.
Matsuzaki G, Umemura M. IL-17 as an effetor molecule of innate and acquired immunity against infections. Microbiol Immunonol. 2007;51:1139–47.
16.
Mathers AR, Tckacheva OA, Janelsins BM, Shufesky WJ, Morelli AE, Larregina AT. In vivo signaling through the neurokinin 1 receptor favors transgene expression by langerhans cells and promotes generation of Th1- and Tc1-biased immune responses. J Immunol. 2007;178:7006–17.PubMed
17.
Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on production of inflammatory cytokines by human onocytes. Science. 1988;241:1218–21.CrossRefPubMed
18.
Herpfer I, Lieb K. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs. 2005;19:275–93.CrossRefPubMed
19.
Khouzam HR. Anxiety disorders: guidelines for effective primary care. Part 1: diagnosis. Consultant. 2009;49(3):1–3.
20.
Boscarino JA. Posttraumatic stress disorder and physical illness: results from clinical and epidemiologic studies. Ann N Y Acad Sci. 2004;1032:141–53.CrossRefPubMed
21.
Sareen J, Cox BJ, Clara I, Asmundson GJ. The relationship between anxiety disorders and physical disorders in the U.S. National Comorbidity Survey. Depress Anxiety. 2005;21:193–202.CrossRefPubMed
22.
Schneiderman N, Ironson G, Siegel SD. Stress and health: psychological, behavioral, and biological determinants. Annu Rev Clin Psychol. 2005;1:607–28.CrossRefPubMed
23.
Godbout JP, Glaser R. Stress-induced immune dysregulation: implications for wound healing, infectious disease and cancer. J Neuroimmune Pharm. 2006;1:421–7.CrossRef
24.
Arranz L, Guayerbas N, De la Fuente M. Impairment of several immune functions in anxious women. J Psychosom Res. 2007;62(1):1–8.CrossRefPubMed
25.
Zhou FL, Zhang WG, Wei YC, Xu KL, Hui LY, et al. Impact of comorbid anxiety and depression on quality of life and cellular immunity changes in patients with digestive tract cancers. World J Gastroenterol. 2005;11(15):2313–8.PubMed
26.
Koh KB, Lee Y. Reduced anxiety level by therapeutic interventions and cell-mediated immunity in panic disorder patients. Psychother Psychosom. 2004;73(5):286–92.CrossRefPubMed
27.
Gill JM, Saligan L, Woods S, Page G. PTSD is associated with an excess of inflammatory immune activities. Perspect Psychiatr Care. 2009;45(4):262–77.CrossRefPubMed
28.
Wessa M, Rohleder N. Endocrine and inflammatory alterations inposttraumatic stress disorder. Expert Rev Endocrinol Metab. 2007;2:91–122.CrossRef
29.
Lemieux A, Coe CL, Carnes M. Symptom severity predicts degree of T cell activation in adult women following childhood maltreatment. Brain Behav Immun. 2008;22(6):994–1003.CrossRefPubMed
30.
Wilson S, van der Kolk B, Burbridge J, Fisler R, Kradin R. Phenotype of blood lymphocytes in PTSD suggests chronic immune activation. Psychosomatics. 1999;40:222–5.PubMed
31.
Boscarino JA, Chang J. Higher abnormal leukocyte and lymphocyte counts 20 years after exposure to severe stress: research and clinical implications. Psychosom Med. 1999;61:378–86.PubMed
32.
Cohen IR, Schwartz M. Autoimmune maintenance and neuroprotection of the central nervous system. J Neuroimmunol. 1999;100:111–4.CrossRefPubMed
33.
Affleck G, Urrows S, Tennen H, Higgins P, Pav D, Aloisi R. A dual pathway model of daily stressor effects on rheumatoid arthritis. Ann Behav Med. 1997;19:161–70.CrossRefPubMed
34.
Kohn PM, Kantor L, DeCicco TL, Beck AT. The beck anxiety inventory-trait (BAIT): a measure of dispositional anxiety not contaminated by dispositional depression. J Person Assessm. 2008;90:499–506.CrossRef
35.
Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50–5.PubMed
36.
Spitzer RL, Williams JB, Gibbon M, First MB. The structured clinical interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry. 1992;49(8):624–9.PubMed
37.
Kang D, Davidson RJ, Coe CL, Wheeler RE, Tomarken AJ, Erschler WB. Frontal brain asymmetry and immune function. Behav Neurosc. 1991;105:860–9.CrossRef
38.
Lemieux AM, Coe CL. Abuse-related post-traumatic stress disorder: evidence of chronic neuroendocrine activation in women. Psychosom Med. 1995;57:105–15.PubMed
39.
Strauman TJ, Lemieux AM, Coe CL. Self-discrepancies and natural killer cell activity: immunological consequences of negative self-evaluation. J Personal Soc Psychol. 1993;64:1042–52.CrossRef
40.
Strauman TJ, Woods TE, Schneider KL, Kwapil L, Coe CL. Self-regulatory cognition and immune reactivity: idiographic success and failure feedback effects on the natural killer cell. Brain Beh Imm. 1993;18:544–54.CrossRef
41.
Lang K, Drell TL, Niggemann B, Zanker KS, Entschladen F. Neurotransmitters regulate the migration and cytotoxicity in natural killer cells. Immunol Lett. 2003;2003(90):165–72.CrossRef
42.
Bastian P, Posch B, Lang K, Niggemann B, Zaenker KS, et al. Phosphatidylinositol 3-kinase in the G protein-coupled receptor-induced chemokinesis and chemotaxis of MDA-MB-468 breast carcinoma cells: a comparison with leukocytes. Mol Cancer Res. 2006;4:411–21.CrossRefPubMed
43.
Bastian P, Balcarek A, Altanis C, Strell C, Niggemann B, et al. The inhibitory effect of norepinephrine on the migration of ES-2 ovarian carcinoma cells involves a Rap1-dependent pathway. Cancer Lett. 2009;274:218–24.CrossRefPubMed
44.
Lang K, Drell TL, Lindecke A, Niggemann B, Kaltschmidt C, et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer. 2004;112:231–8.CrossRefPubMed
45.
Franchimont D, Galon J, Gadina M, Visconti R, Zhou Y, et al. Inhibition of Th1 immune response by glucocorticoids: neurotransmitters selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. J Immunol. 2000;164:1768–74.PubMed
46.
Agarwal SK, Marshall GD. Glucocorticoid-induced type 1/type 2 cytokine alterations in humans: a model for stress-related immune dysfunction. J Interferon Cytokine Res. 1998;18:1059–68.CrossRefPubMed
47.
Lambrecht BN, Germonpre PR, Everaert EG, Carro-Muino I, De Veerman M, et al. Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation. Eur J Immunol. 1999;29:3815–25.CrossRefPubMed
48.
Nio DA, Moylan RN, Roche JK. Modulation of T lymphocyte function by neuropeptides: evidence for their role as local immunoregulatory elements. J Immunol. 1993;150:5281–8.PubMed
49.
Takkouche B, Regueira C, Gestal-Otero JJ. A cohort study of stress and the common cold. Epidemiology. 2001;12:345–9.CrossRefPubMed
50.
Aviles H, Johnson MT, Monroy FP. Effects of cold stress on spleen cell proliferation and cytokine production during chronic Toxoplasma gondii infection. Neuroimmunomodulation. 2004;11(2):93–102.CrossRefPubMed
51.
Cohen F, Kemeny ME, Kearney KA, Zegans LS, Neuhaus JM, Conant MA. Persistent stress as a predictor of genital herpes recurrence. Arch Intern Med. 1999;159:2430–6.CrossRefPubMed
52.
Ben-Eliyahu S. The promotion of tumor metastasis by surgery and tress: immunological basis and implications for psychoneuroimmunology. Brain Behav Immun. 2003;17 Suppl 1:S27–36.CrossRefPubMed
53.
54.
Scholzen TE, Steinhoff M, Sindrilaru A, Schwarz A, Bunnett NW, et al. Cutaneous allergic contact dermatitis responses are diminished in mice deficient in neurokinin 1 receptors and augmented by neurokinin 2 receptor blockage. FASEB J. 2004;18:1007–9.PubMed
55.
Akkoc T, de Koning PJ, Rückert B, Barlan I, Akdis M, Akdis CA. Increased activation-induced cell death of high IFN-gamma-producing T(H)1 cells as a mechanism of T(H)2 predominance in atopic diseases. J Allergy Clin Immunol. 2008;121(3):652–8.CrossRefPubMed
56.
O’Connor JC, André C, Wang Y, Lawson MA, Szegedi SS, et al. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2, 3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci. 2009;29:4200–9.CrossRefPubMed
57.
Dai H, Daí Z. The role of tryptophan catabolism in acquisition and effector function of memory T cells. Cur Opin Organ Transpl. 2008;13:31–5.CrossRef
58.
Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 2000;23:477–501.CrossRefPubMed
59.
Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol. 1999;160:1–12.CrossRefPubMed
60.
Poliak S, Mor F, Conlon P, Wong T, Ling N, et al. Stress and autoimmunity: the neuropeptides corticotrophin releasing factor and urocortin suppress encephalomyelitis via effects on both the hypothalamic-pituitary-adrenal axis the immune system. J Immunol. 1997;158:5751–6.PubMed
61.
Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function. Annu Rev Immunol. 2000;18:309.CrossRefPubMed
62.
Toh MC, Kawashima M, Zrioual S, Hot A, Miossec P. IL-17 inhibits human Th17 differentiation through IL-12 beta 2 downregulation. Cytokine. 2009;48:226–30.CrossRefPubMed
63.
Newcomb DC, Zhou W, Moore ML, Goleniewska K, Hershey GK, et al. A functional IL-13 receptor is expressed on polarized murine CD4+ Th17 cells and IL-13 signaling attenuates Th17 cytokine production. J Immunol. 2009;182:5317–21.CrossRefPubMed
64.
Costantino CM, Baecher-Allan CM, Hafler DA. Human regulatory T cells and autoimmunity. Eur J Immunol. 2008;38:921–4.CrossRefPubMed
65.
Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8:523–32.CrossRefPubMed
66.
Maynard CL, Harrington LE, Janowski KM, Oliver JR, Zindl CL, et al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3-precursor cells in the absence of interleukin 10. Nat Immunol. 2007;8:931–41.CrossRefPubMed
67.
Kitani A, Fuss I, Nakamura K, Kumaki F, Usui T, Strober W. Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis. J Exp Med. 2003;198:1179–88.CrossRefPubMed
68.
Shevach EM. Mechanisms of Foxp3+ T regulatory cell-mediated suppression. Immunity. 2009;30:636–45.CrossRefPubMed
69.
Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol. 2007;7:875–88.CrossRefPubMed
70.
McGeachy MJ, Stephens LA, Anderton SM. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4 + CD25+ regulatory T cells within the central nervous system. J Immunol. 2005;175:3025–32.PubMed
71.
Li MO, Flavell RA. Contextual regulation of inflammation: a duet by transforming growth factor-b and interleukin-10. Immunity. 2008;8:468–76.CrossRef
72.
De Kloet CS, Vermetten E, Geuze E, Kavelaars E, Heijnen A, Westenberg CJ. Assessment of HPA-axis function in posttraumatic stress disorder: pharmacological and non-pharmacological challenge tests, a review. J Psychiatry Res. 2006;40(6):550–67.CrossRef
73.
Burchill MA, Yang J, Vang KB, Farrar MA. Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol Lett. 2007;114:1–8.PubMed
74.
Davidson TS, DiPaolo RJ, Andersson J, Shevach EM. Cutting edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3+ T regulatory cells. J Immunol. 2007;178:4022–6.PubMed
75.
Horwitz DA, Zheng SG, Wang J, Gray JD. Critical role of IL-2 and TGF-beta in generation, function and stabilization of Foxp3 + CD4+ Treg. Eur J Immunol. 2008;38:912–5.CrossRefPubMed
76.
Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity. 2008;29:44–56.CrossRefPubMed
77.
Osorio F, LeibundGut-Landmann S, Lochner M, Lahl K, Sparwasser T, Eberl G, et al. DC activated via dectin-1 convert Treg into IL-17 producers. Eur J Immunol. 2008;38:3274–81.CrossRefPubMed
78.
Nalbandian A, Crispin JC, Tsokos GC. Interleukin-17 and systemic lupus erytematosus: current concepts. Clin Exp Immunol. 2009;157(2):209–15.CrossRefPubMed
79.
Di Cesare A, Di Meglio P, Nestle PD. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339–50.CrossRefPubMed
80.
81.
Liu ZJ, Yadav PK, Su JL, Wang JS, Fei K. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2009;15(46):5784–8.CrossRefPubMed
82.
von Känel R, Hepp U, Kraemer B, Traber R, Keel M, et al. Evidence for low-grade systemic proinflammatory activity in individuals with posttraumatic stress disorder. J Psych Res. 2007;41:744–52.CrossRef
83.
Muller N, Schwarz MJ. Immunology in anxiety and depression. In: Kasper S, den Boer JA, Sitsen JMA, editors. Handbook of depression and anxiety. New York: Marcel Dekker; 2002. p. 267–88.
84.
Sutherland AG, Alexander DA, Hutchison JD. Disturbance of pro-inflammatory cytokines in post-traumatic psychopathology. Cytokine. 2003;24:219–25.CrossRefPubMed
85.
Gill JM, Vythilingam M, Page G. Low cortisol, high DHEA, and high levels of TNF-a and IL-6 in women with PTSD. J Traum Stress. 2008;21(6):530–9.CrossRef
86.
Siebenhaar F, Sharo AA, Peters EMJ, Sharova TY, Syska W, Mardarye AN, et al. Substance P as an immunomodulatory neuropeptide in a mouse model for autoimmune hair loss (Alopecia Areata). J Investig Dermatol. 2007;127:1489–97.CrossRefPubMed
87.
Hordinsky M, Ericson M. Autoimmunity: alopecia areata. J Investig Dermatol Symp Proc. 2004;9:73–8.CrossRefPubMed
88.
Tuncer LI, Alacam T, Oral B. Substance P expression is elevated in inflamed human periradicular tissue. J Endod. 2004;30:329–32.CrossRefPubMed
89.
Felten DL, Felten SY, Bellinger DL, Lorton D. Noradrenergic and peptidergic innervation of secondary lymphoid organs: role in experimental rheumatoid arthritis. Eur J Clin Invest. 1992;22 Suppl 1:37–41.PubMed
90.
Calcagni E, Elenkov I. Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases. Ann NY Acad Sci. 2006;1069:62–76.CrossRefPubMed
91.
Grimsholm O, Rantapää-Dahlqvist S, Dalén T, Forsgren S. Observations favouring the occurrence of local production and marked effects of bombesin/gastrin-releasing peptide in the synovial tissue of the human knee joint—comparisons with substance P and the NK-1 receptor. Neuropeptides. 2008;42(2):133–45.CrossRefPubMed
92.
Rösler N, Reuner C, Geiger J, Rissler K, Cramer H. Cerebrospinal fluid levels of immunoreactive substance P and somatostatin in patients with multiple sclerosis and inflammatory CNS disease. Peptides. 1990;11(1):181–3.CrossRefPubMed
Metadata
Title
Substance P Enhances Th17 Phenotype in Individuals with Generalized Anxiety Disorder: an Event Resistant to Glucocorticoid Inhibition
Authors
Priscila O. Barros
Thais B. Ferreira
Morgana M. M. Vieira
Carla Renata M. Almeida
Carlos Fernando Araújo-Lima
Renato G. Silva-Filho
Joana Hygino
Regis M. Andrade
Arnaldo F. Andrade
Cleonice A. Bento
Publication date
01-02-2011
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 1/2011
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-010-9466-6

Other articles of this Issue 1/2011

Journal of Clinical Immunology 1/2011 Go to the issue

OriginalPaper

Immunochemical Studies on Catechol-Estrogen Modified Plasmid: Possible Role in Rheumatoid Arthritis

OriginalPaper

Nicotine Stimulated Dendritic Cells Could Achieve Anti-Tumor Effects in Mouse Lung and Liver Cancer

OriginalPaper

Primary Immunodeficiencies: A 27-Year Review at a Tertiary Paediatric Hospital in Cape Town, South Africa

OriginalPaper

RANTES Deficiency Attenuates Autoantibody-Induced Glomerulonephritis

OriginalPaper

Interleukin-16 as a Marker of Sézary Syndrome Onset and Stage

OriginalPaper

Expanding the Universe of Cytokines and Pattern Recognition Receptors: Galectins and Glycans in Innate Immunity
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits